Shares more than doubled in value after Phase 3 results suggested Alumis’ pill may compare favorably with other emerging oral ...

Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong ...

In this report, Datamonitor assesses the main events which shaped the psoriasis market in the past five years, and speculates on major events set to impact over the next ten years. Datamonitor focuses ...

Psoriasis causes your body to make new skin cells too quickly. These cells tend to pile up and form spots, bumps, and thick scaly patches called plaques that can be uncomfortable. Scientists think ...

Psoriasis is a chronic, immune-mediated condition. It typically affects the skin, but can also have implications for other organ systems, including the joints. When psoriasis affects the skin, it ...

NB-UVB phototherapy may restore adalimumab efficacy in chronic plaque psoriasis after treatment failure. Learn more about ...